Antiandrogen Therapy Abiraterone Acetate and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

  • End date
    Nov 16, 2022
  • participants needed
  • sponsor
    University of Washington
Updated on 26 January 2021
ct scan
endocrine therapy
gilbert's syndrome
neutrophil count
hormone therapy
tumor cells
antiandrogen therapy
androgen suppression
bone scan
cancer treatment
androgen ablation


This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering with the action of hormones. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. It is not yet known whether antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy may work better in treating patients with prostate cancer.


OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 4 weeks for 6 months.

Condition Bone Metastases, Prostate Adenocarcinoma, Metastatic Malignant Neoplasm in the Bone, Adenocarcinoma of the Prostate, Bone Metastasis, Adenocarcinoma of Prostate, Metastatic Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Cancer Metastatic, Castration Resistant Prostate Cancer, Prostate Small Cell Carcinoma, Castration-Sensitive Prostate Carcinoma, Castration-Sensitive Prostate Carcinoma, Castration-Sensitive Prostate Carcinoma
Treatment radiation therapy, prednisone, Abiraterone, antiandrogen therapy, abiraterone acetate
Clinical Study IdentifierNCT03649841
SponsorUniversity of Washington
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you male?
Do you have any of these conditions: Castration-Sensitive Prostate Carcinoma or Metastatic Prostate Carcinoma or Metastatic Malignant Neoplasm in the Bone or Castration Resistant Prostate...?
Do you have any of these conditions: Adenocarcinoma of the Prostate or Bone Metastasis or Metastatic Prostate Cancer or Metastatic Malignant Neoplasm in the Bone or Prostate Carcinoma Met...?
Pathologically proven (either histologic or cytologic) diagnosis of prostate adenocarcinoma with < 50% neuroendocrine differentiation or small cell histology
At least one site of nodal or distant metastatic disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, or a bony metastasis that is evaluable on both computed tomography (CT) and bone scan
No prior orchiectomy
No androgen deprivation therapy such as treatment with antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists or antagonists for at least one year prior to trial enrollment, and testosterone must be inside normal range prior to trial enrollment if there is prior history of ADT
No other systemic anti-cancer therapy for at least 1-year prior to enrollment
Prior prostate-directed therapies such as prostatectomy or cryotherapy are allowed
Prior radiation treatments are allowed (prostate or metastatic sites) but must have been completed at least 3 months prior to starting ADT for this trial
White blood cell (WBC) > 3000/mm^3
Absolute neutrophil count (ANC) > 1000/mm^3
Platelets > 100,000/mm^3
Creatinine < 1.5 institutional upper limit of normal (ULN) or calculated creatinine clearance > 30 ml/min
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin < 3 x institutional ULN (unless patient has documented Gilbert's syndrome)
No steroids for at least 2 weeks prior to enrollment, and patient must not be expected to require steroids during the study period, other than the typical low dose steroid that is given with abiraterone (typically prednisone or prednisolone at 5 mg twice daily)
Zubrod performance status 0-2
Patient must sign study specific informed consent prior to study entry
Men who are sexually active must use medically acceptable forms of contraception

Exclusion Criteria

Other illnesses with a life expectancy of less than 6 months, including but not limited to unstable angina, symptomatic congestive heart failure, cardiac arrhythmias
Psychological or social issues that would prevent patients from informed consent or complying with study requirements
Subject has a history of unexplained loss of consciousness or transient ischemic attack within 12 months of treatment start
Individuals on active treatment for a different cancer are excluded. Individuals with a history of other malignancies are eligible if they are deemed by the investigator to be at low risk for recurrence of that malignancy
Known brain metastasis
Known allergies, hypersensitivity, or intolerance to abiraterone or prednisone
Prior ADT less than a year, or greater than two months, prior to trial enrollment or prior ADT with testosterone less than normal
There is a potential drug interaction when abiraterone is concomitantly used with a CYP2D6 substrate narrow therapeutic index (e.g., thioridazine, dextromethorphan), or strong CYP3A4 inhibitors (e.g., atazanavir, erythromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) or strong inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine). Caution should be used when patients are on one of these drugs
Patients with a history of pituitary or adrenal dysfunction, active or symptomatic viral hepatitis, human immunodeficiency virus (HIV), or chronic liver disease are not eligible
Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/prednisolone once daily
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note